Xofluza for Acute Uncomplicated Influenza

News
Article
Drug Topics JournalDrug Topics March 2019
Volume 163
Issue 3

Xofluza Product Boxes

Xofluza (baloxavir marboxil, Genetech)

Indications: acute uncomplicated influenza in patients 12+, <48hr symptomatic

Dosage:

  • 40-80kg body = 40 mg

  • 80kg+ = 80 mg

Contraindications: history of hypersensitivity to baloxair marboxil or any of its ingredients

Click here for more prescribing information

Download Issue PDF
Articles in this issue
Grief
Coping with Patient Death
Clock
Opinion: Why Change Is Like a Hemorrhoidectomy
Pharmacist Behind Counter
Pharmacists Want More Time with Patients
Health System
The Pros and Cons of Switching to a Health System
Elderly Couple in Park
Early Planning is Key to Retirement and Succession
Dietary Supplements
Dietary Supplements Need Evidence and Evaluation
Coffee Cups
Reconnect to Reinvigorate
Book shelves
Pharmacy Education for the 21st Century
March Cover Image
How to Achieve Balance in Work and in Life
Slippers
Case Studies in Stability
Patient Doctor Medication
Opinion: Avoiding "White Coat Marketing" Accusations
Xofluza Product Boxes
Xofluza for Acute Uncomplicated Influenza

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
Related Content
FDA Approves Finerenone for Heart Failure With Left Ventricular Ejection Fraction

FDA Approves Finerenone for Heart Failure With Left Ventricular Ejection Fraction

Ashley Gallagher
July 14th 2025
Article

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Sebetralstat for Hereditary Angioedema

FDA Approves Sebetralstat for Hereditary Angioedema

Killian Meara
July 7th 2025
Article

The therapy is now the first and only oral on demand treatment option for the condition.

Increased COVID-19 Testing Skewed Understanding of Respiratory Disease Trends

Increased COVID-19 Testing Skewed Understanding of Respiratory Disease Trends

Brian Nowosielski
July 7th 2025
Article

Researchers determined the impact COVID-19 interventions had on Danish children’s incidence of RSV, influenza, and invasive pneumococcal disease.

ACIP Votes Against Thimerosal Vaccines for Prevention of Influenza

ACIP Votes Against Thimerosal Vaccines for Prevention of Influenza

Ashley Gallagher
June 27th 2025
Article

ACIP also discusses COVID-19 epidemiology as well as safety and efficacy for the COVID-19 vaccines.

Subcutaneous Injection Shows Prevention of Flu in Phase 2b Trial

Subcutaneous Injection Shows Prevention of Flu in Phase 2b Trial

Ashley Gallagher
June 26th 2025
Article

CD388 is being investigated as a prevention method for seasonal influenza in unvaccinated patients aged 18 to 64 years.

© 2025 MJH Life Sciences

All rights reserved.